TY - JOUR
T1 - Value for money of medicine sampling and quality testing
T2 - Evidence from Indonesia
AU - Valente De Almeida, Sara
AU - Hauck, Katharina
AU - Njenga, Sarah
AU - Nugrahani, Yunita
AU - Rahmawati, Ayu
AU - Mawaddati, Rahmi
AU - Saputra, Stanley
AU - Hasnida, Amalia
AU - Pisani, Elizabeth
AU - Anggriani, Yusi
AU - Gheorghe, Adrian
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2024.
PY - 2024/9/23
Y1 - 2024/9/23
N2 - Background Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM? Methods Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines' regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online). Results The total cost of sampling and testing medicines from the market was US712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US479 (95% CI US462 to US516) to collect one medicine sample and US5990 (95% CI US5601 to US6258) to identify one substandard sample. Conclusion Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.
AB - Background Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM? Methods Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines' regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online). Results The total cost of sampling and testing medicines from the market was US712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US479 (95% CI US462 to US516) to collect one medicine sample and US5990 (95% CI US5601 to US6258) to identify one substandard sample. Conclusion Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.
UR - http://www.scopus.com/inward/record.url?scp=85205900615&partnerID=8YFLogxK
U2 - 10.1136/bmjgh-2024-015402
DO - 10.1136/bmjgh-2024-015402
M3 - Article
C2 - 39313254
AN - SCOPUS:85205900615
SN - 2059-7908
VL - 9
JO - BMJ Global Health
JF - BMJ Global Health
IS - 9
M1 - e015402
ER -